TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors Natalia SauerNatalia JanickaKatarzyna Karłowicz-Bodalska Review Open access 11 August 2023 Pages: 3405 - 3425
Cancer management during the COVID-19 world pandemic Navid SobhaniGiuseppina MondaniDaniele Generali Review 29 August 2023 Pages: 3427 - 3444
Radiation-associated secondary malignancies: a novel opportunity for applying immunotherapies Tavus AtajanovaMd Mahfuzur RahmanZachary S. Morris Review 02 September 2023 Pages: 3445 - 3452
Metabolic diversity of tumor-infiltrating T cells as target for anti-immune therapeutics Peipei LiFangchao LiJingjing Li Review 21 September 2023 Pages: 3453 - 3460
BTK inhibition potentiates anti-PD-L1 treatment in murine melanoma: potential role for MDSC modulation in immunotherapy Steven H. SunColin D. AngellWilliam E. Carson III Research 02 August 2023 Pages: 3461 - 3474
Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections C. SchmittE. P. HoefsmitL. M. Heinzerling Research Open access 22 August 2023 Pages: 3475 - 3489
Systemic administration of STING agonist promotes myeloid cells maturation and antitumor immunity through regulating hematopoietic stem and progenitor cell fate Tianxiao XuJie DaiJun Guo Research 07 August 2023 Pages: 3491 - 3505
Deciphering the immune reaction leading to spontaneous melanoma regression: initial role of MHCII+ CD163− macrophages Fany BlancNicolas BerthoArmelle Prévost-Blondel Research Open access 01 August 2023 Pages: 3507 - 3521
Role of single-cell ferroptosis regulation in intercellular communication and skin cutaneous melanoma progression and immunotherapy Binyu SongYixuan PengBaoqiang Song Research 28 August 2023 Pages: 3523 - 3541
Preferential B cell differentiation by combined immune checkpoint blockade for renal cell carcinoma is associated with clinical response and autoimmune reactions Koki UeharaKenro TanoueEishi Baba Research 07 August 2023 Pages: 3543 - 3558
HLA-B*44 and the Bw4-80T motif are associated with poor outcome of relapse-preventive immunotherapy in acute myeloid leukemia Hana KomicAlexander HallnerFredrik B. Thorén Research Open access 19 August 2023 Pages: 3559 - 3566
A novel agonist of 4-1BB costimulatory receptor shows therapeutic efficacy against a tobacco carcinogen-induced lung cancer Ayse Ece GulenRakesh RudraboinaEsma S. Yolcu Research 22 August 2023 Pages: 3567 - 3579
Thrombotic risk of platinum combination chemotherapy with and without immune checkpoint inhibitors for advanced non-small cell lung cancer: a nationwide inpatient database study Chikako IwaiTaisuke JoHideo Yasunaga Research Open access 04 August 2023 Pages: 3581 - 3591
Reovirus combined with a STING agonist enhances anti-tumor immunity in a mouse model of colorectal cancer Naomi SugimuraEiji KubotaHiromi Kataoka Research 01 August 2023 Pages: 3593 - 3608
Transarterial interventional therapy combined with tyrosine kinase inhibitors with or without anti-PD-1 antibodies as initial treatment for hepatocellular carcinoma with major portal vein tumor thrombosis: a single-center retrospective study Wenchang YuWeifu LiuXiaolong Wang Research 11 August 2023 Pages: 3609 - 3619
Th1 cytokines in pediatric acute lymphoblastic leukemia Sarah SchoberJennifer M. RottenbergerManon Queudeville Research Open access 23 August 2023 Pages: 3621 - 3634
Comparison of the effectiveness of chemotherapy combined with immunotherapy and chemotherapy alone in advanced biliary tract cancer and construction of the nomogram for survival prediction based on the inflammatory index and controlling nutritional status score Zhengfeng ZhangDazhen WangChangjie Lou Research Open access 05 September 2023 Pages: 3635 - 3649
Intravenous injection of tumor extracellular vesicles suppresses tumor growth by reducing the regulatory T cell phenotype Sanshiro KobayashiNaoyuki KondoMakoto Naganuma Research 19 August 2023 Pages: 3651 - 3664
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study Ondřej FialaSebastiano ButiMatteo Santoni Research 07 September 2023 Pages: 3665 - 3682
Nomogram for predicting the prognosis of metastatic colorectal cancer patients treated with anti-PD1 therapy based on serum lipids analysis Bijing XiaoHui OuyangYan Huang Research Open access 17 August 2023 Pages: 3683 - 3692
Reconstructing the immunosenescence core pathway reveals global characteristics in pan-cancer Yakun ZhangYue SunXia Li Research 22 August 2023 Pages: 3693 - 3705
Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE study Melissa BersanelliAlessio CortelliniSebastiano Buti Research Open access 28 August 2023 Pages: 3707 - 3716
Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: effectiveness, safety, and biomarker analysis Jiashuo ChaoShanshan WangHaitao Zhao Research 03 October 2023 Pages: 3717 - 3726
Combination therapy with dendritic cell loaded-exosomes supplemented with PD-1 inhibition at different time points have superior antitumor effect in hepatocellular carcinoma Chunxiao ChangYanqing PeiShengbin Shi Research 04 September 2023 Pages: 3727 - 3738
Anti-CD79b/CD3 bispecific antibody combined with CAR19-T cells for B-cell lymphoma treatment Wei-Wei ZhengHang ZhouCai-Wen Duan Research 14 September 2023 Pages: 3739 - 3753
Prognostic impact of soluble PD-L1 derived from tumor-associated macrophages in non-small-cell lung cancer Koji TeramotoTomoyuki IgarashiYataro Daigo Research Open access 30 August 2023 Pages: 3755 - 3764
Second-line immunosuppressant administration for steroid-refractory immune-related adverse events in patients with lung cancer Shinsuke OgusuYuhei HarutaniRyo Ariyasu Research Open access 28 August 2023 Pages: 3765 - 3772
Dual targeting ovarian cancer by Muc16 CAR T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1 Sung Soo MunJeremy MeyerbergDavid A. Scheinberg Research 27 August 2023 Pages: 3773 - 3786
PD-L1-expressing cancer-associated fibroblasts induce tumor immunosuppression and contribute to poor clinical outcome in esophageal cancer Kento KawasakiKazuhiro NomaToshiyoshi Fujiwara Research Open access 05 September 2023 Pages: 3787 - 3802
Leptin-mediated meta-inflammation may provide survival benefit in patients receiving maintenance immunotherapy for extensive-stage small cell lung cancer (ES-SCLC) Emanuele VitaAlessio StefaniEmilio Bria Research Open access 05 September 2023 Pages: 3803 - 3812
Targeting GD2 after allogeneic SCT: effector cell composition defines the optimal use of ch14.18 and the bispecific antibody construct NG-CU (GD2-CD3) A.-M. ArendtF. HeubachP. Lang Research Open access 24 September 2023 Pages: 3813 - 3824
GK-1 effectively reduces angiogenesis and prevents T cell exhaustion in a breast cancer murine experimental model Juan A. Hernández-AcevesJacquelynne Cervantes-TorresEdda Sciutto Research Open access 22 September 2023 Pages: 3825 - 3838
Extended duration of treatment using reduced-frequency dosing of anti-PD-1 therapy in patients with advanced melanoma and Merkel cell carcinoma Lisa May Ling TachikiDaniel S. HippeShailender Bhatia Research Open access 21 September 2023 Pages: 3839 - 3850
Radiation-induced dormancy of intracerebral melanoma: endotoxin inflammation leads to both shortened tumor dormancy and long-term survival with localized senescence Sharif M. RidwanRose EmleinHenry M. Smilowitz Research Report 23 August 2023 Pages: 3851 - 3859
Pretreatment blast-to-lymphocyte ratio as a prognostic marker for CD19/CD3-bispecific T cell-engaging antibodies (blinatumomab) treatment against relapsed or refractory B-precursor acute lymphoblastic leukemia Yutaka ShimazuToshio KitawakiAkifumi Takaori-Kondo Brief Report 07 August 2023 Pages: 3861 - 3865
Immune profile of patients with peritoneal carcinomatosis selected for CRS-HIPEC therapy Julia KleberJordi Yang ZhouJens M. Werner Brief Report Open access 14 August 2023 Pages: 3867 - 3873
